New drug under observation for rare genetic disorder
Disease control
ENROLLING_BY_INVITATION
This study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers will track side effects and how the drug affects their health over time. The goal is to gather more safety information, not to test if the drug cures the condition.
Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC